This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by HUNNINGHAKE, D. B. Articles by AZARNOFF, D. L. Search for Related Content PubMed PubMed Citation Articles by HUNNINGHAKE, D. B. Articles by AZARNOFF, D. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL

(Circulation. 1969;39:675.)
© 1969 American Heart Association, Inc.

---

Long-Term Effects of Clofibrate (Atromid-S) on Serum Lipids in Man

DONALD B. HUNNINGHAKE M.D.¹; DONALD R. TUCKER M.D.¹; DANIEL L. AZARNOFF M.D.¹

¹ From the Departments of Medicine and Pharmacology, University of Kansas Medical Center, Kansas City, Kansas.

Clofibrate was administered to 45 patients for varying periods of time up to 4 years with no evidence of chronic toxicity. Clofibrate was more effective in lowering serum triglycerides than serum cholesterol, with more than 75% of all patients with elevated triglycerides having at least a 25% reduction in triglycerides, the absolute reduction in triglycerides being directly correlated with pretreatment values. A reduction in serum cholesterol of 15% or more was obtained in 50% of all patients, those individuals with elevations of triglycerides having the greatest reduction in serum cholesterol as well as being most likely to respond.

Key Words: Hyperlipidemia therapy